Ira Bergman
Psychiatry · Ny, NYNPI 1568566552
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 51.0% of the total. Reporting peaked in 2022 at $12,405 and has fallen 93.3% since, to $835 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $42.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$12K
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$2K
- Validus Pharmaceuticals LLC$1K
- Bausch Health US, LLC$1K
- Johnson & Johnson$899
- plus $5K from 25 others
What the payments were for
- Speaking & faculty fees$10,50044%
- Travel & lodging$9224%
- Food & beverage$12,59752%
- Education$490%
- Gifts$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 40 | $12,267 |
| AbbVie(2 entities) | 99 | $1,758 |
| Sunovion Pharmaceuticals Inc. | 82 | $1,668 |
| Validus Pharmaceuticals LLC | 36 | $1,495 |
| Bausch Health US, LLC | 61 | $1,007 |
| Johnson & Johnson | 23 | $899 |
| Lundbeck LLC | 54 | $868 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $685 |
| Corium, LLC | 26 | $597 |
| Otsuka America Pharmaceutical, Inc. | 22 | $429 |
| Vanda Pharmaceuticals Inc. | 20 | $424 |
| Alkermes, Inc. | 6 | $244 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $208 |
| Shire North American Group Inc | 13 | $203 |
| Teva Pharmaceuticals USA, Inc. | 5 | $192 |
| Ironshore Pharmaceuticals Inc. | 8 | $153 |
| Kyowa Kirin, Inc. | 1 | $125 |
| Neos Therapeutics, LP | 6 | $121 |
| Eisai Inc. | 5 | $118 |
| Almatica Pharma LLC | 4 | $94 |
| Adlon Therapeutics L.p. | 5 | $87 |
| Neurocrine Biosciences, Inc. | 4 | $86 |
| Abbott | 1 | $75 |
| Idorsia Pharmaceuticals US Inc | 3 | $69 |
| Avanir Pharmaceuticals, Inc. | 3 | $52 |
| Aytu Biopharma, Inc. | 2 | $34 |
| Vertical Pharmaceuticals, LLC | 2 | $32 |
| Noven Therapeutics, LLC | 2 | $30 |
| Biogen | 1 | $18 |
| Merck | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,070 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AplenzinBupropion Hbr | 12 | $33,568 |
| TrintellixVortioxetine Hydrobromide | 54 | $33,121 |
| RexultiBrexpiprazole | 12 | $15,617 |
| Lurasidone Hcl | 17 | $9,886 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $9,466 |
| ViibrydVilazodone Hcl | 14 | $4,883 |
| Bupropion XlBupropion Hcl | 182 | $4,785 |
| Clonazepam | 249 | $3,292 |
| Doxepin Hcl | 32 | $2,335 |
| Vilazodone Hcl | 13 | $1,490 |
| Aripiprazole | 68 | $1,328 |
| Duloxetine Hcl | 64 | $1,204 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 63 | $1,157 |
| Escitalopram Oxalate | 68 | $1,093 |
| Lamotrigine | 77 | $1,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $685 | $42,58770 claims |
| Bausch Health US, LLCAplenzin | $1,007 | $33,56812 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $429 | $15,61712 claims |
| AbbVieViibryd | $1,758 | $4,88314 claims |
| Almatica Pharma LLCSertraline Hcl | $94 | $875100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Ny
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.